한국형 양극성 장애 약물치료 알고리듬 2022: 조증 삽화
Korean Medication Algorithm Project for Bipolar Disorder 2022: Manic Episode
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) is a consensus- based medication guideline. To reflect advances in pharmacotherapy for bipolar disorders, we updated KMAP-BP to provide more timely information for clinicians. Methods We conducted a survey using a questionnaire on treatments formanic/hypomanic episodes. Eighty-seven members among ninety-three members of the review committee (93.5%) completed the survey. Each treatment strategy or treatment option for manic/hypomanic episodes was evaluated with an overall score of 9, and the resulting 95% confidence interval treatment options were categorized into three recommendation levels (primary, secondary, and tertiary). The executive committee analyzed the results and discussed the final production of an algorithm by considering the scientific evidence. Results The combination of a mood stabilizer and an atypical antipsychotic, monotherapy with a mood stabilizer, or monotherapy with an atypical antipsychotic were recommended as the firstline pharmacotherapeutic strategy for the initial treatment of mania without psychotic features. The mood stabilizer and atypical antipsychotic combination was the treatment of choice, and atypical antipsychotic monotherapy was the first-line treatment for mania with psychotic features. When initial treatment fails, a combination of mood stabilizer+atypical antipsychotic and switching to another first-line agent is recommended. For hypomania, monotherapy with either mood stabilizer or atypical antipsychotic is the recommended first-line treatment, but the mood stabilizer+atypical antipsychotic combination is recommended as well. Conclusion It is notable that there were changes in the preferences for the use of individual atypical antipsychotics, and the preference for the use of mood stabilizer increased for treatment- resistant mania.
Abstract
Objectives The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) is a consensus- based medication guideline. To reflect advances in pharmacotherapy for bipolar disorders, we updated KMAP-BP to provide more timely information for clinicians. Methods We conducted a survey using a questionnaire on treatments formanic/hypomanic episodes. Eighty-seven members among ninety-three members of the review committee (93.5%) completed the survey. Each treatment strategy or treatment option for manic/hypomanic episodes was evaluated with an overall score of 9, and the resulting 95% confidence interval treatment options were categorized into three recommendation levels (primary, secondary, and tertiary). The executive committee analyzed the results and discussed the final production of an algorithm by considering the scientific evidence. Results The combination of a mood stabilizer and an atypical antipsychotic, monotherapy with a mood stabilizer, or monotherapy with an atypical antipsychotic were recommended as the firstline pharmacotherapeutic strategy for the initial treatment of mania without psychotic features. The mood stabilizer and atypical antipsychotic combination was the treatment of choice, and atypical antipsychotic monotherapy was the first-line treatment for mania with psychotic features. When initial treatment fails, a combination of mood stabilizer+atypical antipsychotic and switching to another first-line agent is recommended. For hypomania, monotherapy with either mood stabilizer or atypical antipsychotic is the recommended first-line treatment, but the mood stabilizer+atypical antipsychotic combination is recommended as well. Conclusion It is notable that there were changes in the preferences for the use of individual atypical antipsychotics, and the preference for the use of mood stabilizer increased for treatment- resistant mania.
참고문헌 (19)
- 박원명, "양극성 장애의 한국형 약물치료 알고리듬", 대한정신약물학회지, 13(3), pp.205~221 (2002), 대한정신약물학회
- 안용민, "정신분열병 약물 치료에 대한 한국형 알고리듬의 개발 계획", 대한정신약물학회지, 14(2), pp.108~118 (2003), 대한정신약물학회
- Jon DI, "Revised Korean medication algorithm for bipolar disorder", World J Biol Psychiatry, 10(4 Pt 3), pp.846~855 (2009)
- Shin YC, "Korean medication algorithm for bipolar disorder : second revision", Asia Pac Psychiatry, 5, pp.301~308 (2013)
- Woo YS, "Korean medication algorithm project for bipolar disorder : third revision", Neuropsychiatr Dis Treat, 11, pp.493~506 (2015)
- Young Sup Woo, "Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision", Clinical Psychopharmacology and Neuroscience, 16(4), pp.434~448 (2018), 대한정신약물학회[DOI]
- Sachs GS, "The expert consensus guideline series: medication treatment of bipolar disorder 2000", Postgrad Med, (Spec No), pp.1~104 (2000)[DOI]
- Brook RH, "A method for the detailed assessment of the appropriateness of medical technologies", Int J Technol Assess Health Care, 2, pp.53~63 (1986)
- 김찬형, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅰ)：전반적 평가", 대한정신약물학회지, 16(3), pp.225~233 (2005), 대한정신약물학회
- 신영철, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅱ)：약물의 선택", 대한정신약물학회지, 16(4), pp.285~291 (2005), 대한정신약물학회
- 전덕인, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅲ)：치료반응과 내약성", 대한정신약물학회지, 16(4), pp.292~300 (2005), 대한정신약물학회
- Kishi T, "Pharmacological treatment for bipolar mania : a systematic review and network meta-analysis of double-blind randomized controlled trials", Mol Psychiatry, 27, pp.1136~1144 (2022)
- Yildiz A, "A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania", Psychol Med, 45, pp.299~317 (2015)
- Kadakia A, "Efficacy and tolerability of atypical antipsychotics for acute bipolar depression : a network meta-analysis", BMC Psychiatry, 21, pp.249~ (2021)
- Ward K, "The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy", Expert Opin Investig Drugs, 29, pp.245~257 (2020)
- de Bartolomeis A, "Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder : from acute mania to long-term maintenance", Expert Opin Pharmacother, 13, pp.2027~2036 (2012)
- Fountoulakis KN, "The CINP guidelines on the definition and evidence-based interventions for treatment-resistant bipolar disorder", Int J Neuropsychopharmacol, 23, pp.230~256 (2020)
- Norio Yasui-Furukori, "Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder", Clinical Psychopharmacology and Neuroscience, 18(4), pp.599~606 (2020), 대한정신약물학회[DOI]
- Malhi GS, "The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary", Bipolar Disord, 22, pp.805~821 (2020)